top of page

METABOLIC MRI IS EMPOWERED BY HYPERPOLARIZATION.
NVISION MAKES IT SIMPLE.

Hyperpolarization enables rapid, precise measurement of natural metabolites. NVision provides fast, robust and easy-to-use hyperpolarization technology for preclinical and clinical research and clinical applications.

POLARIS OFFERS:

Nvision-Icon.png

High throughput (3min per dose)

Nvision-Icon.png

Convenient, room temperature processing

Nvision-Icon.png

Small footprint, no infrastructure adjustment

Nvision-Icon.png

Simple, robust workflow

Preclinical Polarizer_4000x3000_front-shadow-1.png

Preclinical POLARIS delivery from 2024

Clinical POLARIS following in 2025

Nvision-BG-Panels.jpg

POLARIS IS
BASED ON PHIP.

NVision is enabling room-temperature hyperpolarization in 3 minutes based on parahydrogen-induced polarization (PHIP) by combining deep expertise in spin quantum physics, chemistry and engineering.

ManipulateSpin.png
Rectangle 196.png

The power source of PHIP is parahydrogen, a quantum state of hydrogen (singlet state), produced off-site and provided by NVision.

STEP 1
MANIPULATE SPIN-STATE CENTRALLY

11012024_Website-Images_Step-3 (1).jpg
Rectangle 196.png

Polarization is transferred to a natural metabolite by catalytically adding parahydrogen to a precursor.

STEP 3
TRANSFER POLARIZATION

ShipToUser.png
Rectangle 196.png

Parahydrogen is stored in aluminum bottles and shipped to the users. NVision's technology ensures that parahydrogen stays stable for months.

STEP 2
SHIP TO USERS

11012024_Website-Images_Step-4 (2).jpg
Rectangle 196.png

After purification, the hyperpolarized metabolite, e.g. pyruvate, is ready for injection.

STEP 4
PURIFY AND RELEASE

POLARIS FOR PRECLINICAL USE

NVISION PROVIDES AN END-TO-END SOLUTION, ENABLING FAST RAMP-UP
IN YOUR LAB.

POLARIZER

Preclinical Polarizer_4000x3000_front-shadow-1.png

CONSUMABLES

Active ingredients
Ready to use 13C-pyruvate precursor and catalyst

Drug Vial_NV LogoAND13C pyruvate precursor_WithoutBackground.png
HydrogenCylinder_bw_light.png

Parahydrogen cylinders

SUPPORT

Nvision-Icon.png
Nvision-Icon.png
Nvision-Icon.png
Nvision-Icon.png
Nvision-Icon.png

Service
Maintenance
Training
Consulting
Research Collaboration

DOSE PRODUCTION IN THREE SIMPLE STEPS

TECHNICAL SPECIFICATIONS

>15% at the time of injection

Polarization

3 options available: (a) 0.8 mL at 80 mM, (b) 1 mL at 160mM, (c) 2 mL at 80 mM

Produced Dose

3 minutes for dose production, 15 minutes dose-to-dose interval (incl. cleaning)

Process Time

Integrated fluidic control, no manual manipulation required, semi-automated cleaning after each dose

Fluidic Control

13C-pyruvate precursor, Rh-catalyst,
Parahydrogen gas in multi-dose standard cylinder

Consumables
supplied by NVision

Standard reagents (NVision supports purchasing)
N   in a standard cylinder or wall outlet

2

Other Consumables

H 195 cm / W 90 cm / D 85 cm, Weight 350 kg // Footprint < 1 m

2

Dimensions

Fits in standard elevators, can be wheeled between MRI labs

Transportability

Standard power supply, installation outside of 5 G line

Installation

Certification

Fulfills relevant US / EU certifications for laboratory equipment

* subject to change

13C-Pyruvate

Probe

NVISION'S POLARIZATION PLATFORM PROVIDES EXCELLENT DATA IN UNPRECEDENTED THROUGHPUT AND ROBUSTNESS.

COMPARISON OF PHIP / d-DNP SPECTROSCOPY

Graph - left-05.png

MATBIII model (Rat)

Integrated signal intensities over time from dynamic spectroscopy of a slice containing only the tumor of a subcutaneous MATBIII model (Rat).

Graph - right-03.png

EL4 lymphoma model (Mouse)

Integrated signal intensities over time from dynamic spectroscopy of a slice containing only the tumor of a subcutaneous EL4 lymphoma model (Mouse).

Wolfgang Gottwald, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.

COMPARISON OF PHIP / d-DNP IMAGING

Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany

NEW APPLICATIONS ARE NOW ENABLED BY FAST DOSE PRODUCTION (4 INJECTIONS WITHIN 1 HOUR).

Wolfgang Gottwald, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.

MATBIII breast cancer model (Rat)

Dynamic spectroscopy of tumor slice after four injections of PHIP pyruvate.
Pyruvate peaks normalized to 1.

FOR MORE INFORMATION
CONNECT WITH US.

Thanks for submitting!

FEATURES IN LEADING JOURNALS
AND PRESS RELEASES

nVISION_FEATURES.png
nVISION_FEATURES.png
nVISION_FEATURES.png
nVISION_FEATURES.png
ScienceLogo1.jpg
bottom of page